A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO) (VOLUME-PRO)
2 de mayo de 2022 actualizado por: Bristol-Myers Squibb
Nivolumab in the Real World in Patients With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO)
The purpose of the study is to capture the utilization of nivolumab among participants with squamous cell carcinoma of the head and neck (SCCHN) since its approval, and to describe the health related quality of life (HRQoL) among participants treated with nivolumab in a real-world setting.
Descripción general del estudio
Estado
Terminado
Intervención / Tratamiento
Descripción detallada
This is a phase 4 prospective chart review study with patient reported outcome (PRO) administration.
The study population consists of participants diagnosed with squamous cell carcinoma of the head and neck (SCCHN) and are being treated with nivolumab.
Eligible participants will be enrolled and observed from enrollment up to eight weeks.
Demographic and clinical characteristics will be collected at enrollment.
PROs will be administered at enrollment and again at a follow-up standard of care visit approximately eight weeks after enrollment.
Tipo de estudio
De observación
Inscripción (Actual)
509
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
New Jersey
-
Mount Laurel, New Jersey, Estados Unidos, 08054
- Local Institution
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Método de muestreo
Muestra no probabilística
Población de estudio
The population for this study will be approximately 50 adult participants, with a diagnosis of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) currently being treated with nivolumab in the United Kingdom, Switzerland, Spain, or Canada.
The study population will include participants with available data from medical records at enrollment who are willing to complete patient reported outcome (PRO) assessments.
Descripción
Inclusion Criteria:
- Diagnosis of recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN)
- Age ≥18 years at time of nivolumab treatment initiation
- Investigator has decided that nivolumab is appropriate therapy and the participant had received at least one administration of nivolumab for the treatment of recurrent/metastatic SCCHN prior to enrolment in the study
- Charts/records include treatment start date of nivolumab
- Provide consent and is willing to self-complete on-site patient reported outcomes (PROs) on at least one occasion
Exclusion Criteria:
- Currently enrolled in an interventional clinical trial for their SCCHN
- Received systemic treatment for any other primary cancer within 6 months of study enrolment
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: Grupo
- Perspectivas temporales: Futuro
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Cohort 1
Participants with squamous cell carcinoma of the head and neck (SCCHN) treated with nivolumab
|
Participants in this study are being treated with nivolumab for SCCHN
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Distribution of demographic characteristics of R/M SCCHN participants treated with nivolumab: Month and year of birth
Periodo de tiempo: At enrollment
|
Recurrent/Metastatic (R/M) Squamous Cell Carcinoma of the Head & Neck (SCCHN)
|
At enrollment
|
|
Distribution of demographic characteristics of R/M SCCHN participants treated with nivolumab: Sex
Periodo de tiempo: At enrollment
|
At enrollment
|
|
|
Distribution of demographic characteristics of R/M SCCHN participants treated with nivolumab: Race/ethnicity
Periodo de tiempo: At enrollment
|
At enrollment
|
|
|
Distribution of demographic characteristics of R/M SCCHN participants treated with nivolumab: Smoking status
Periodo de tiempo: At enrollment
|
At enrollment
|
|
|
Distribution of clinical characteristics of R/M SCCHN participants treated with nivolumab: Primary tumor location
Periodo de tiempo: At enrollment
|
At enrollment
|
|
|
Distribution of clinical characteristics of R/M SCCHN participants treated with nivolumab: Metastasis locations
Periodo de tiempo: At enrollment
|
At enrollment
|
|
|
Distribution of clinical characteristics of R/M SCCHN participants treated with nivolumab: Histology
Periodo de tiempo: At enrollment
|
At enrollment
|
|
|
Distribution of clinical characteristics of R/M SCCHN participants treated with nivolumab: Date of diagnosis of R/M SCCHN
Periodo de tiempo: At enrollment
|
At enrollment
|
|
|
Distribution of clinical characteristics of R/M SCCHN participants treated with nivolumab: Stage at locally advanced/metastatic SCCHN diagnosis
Periodo de tiempo: At enrollment
|
At enrollment
|
|
|
Distribution of patterns of use of nivolumab treatment in participants with R/M SCCHN: Duration of nivolumab therapy
Periodo de tiempo: Up to 8 weeks following enrollment
|
Up to 8 weeks following enrollment
|
|
|
Distribution of patterns of use of nivolumab treatment in participants with R/M SCCHN: Drug discontinuation
Periodo de tiempo: Up to 8 weeks following enrollment
|
Up to 8 weeks following enrollment
|
|
|
Distribution of doses of nivolumab therapy in participants with R/M SCCHN
Periodo de tiempo: Up to 8 weeks following enrollment
|
Up to 8 weeks following enrollment
|
|
|
Distribution of subsequent treatment in participants discontinuing nivolumab
Periodo de tiempo: Up to 8 weeks following enrollment
|
Up to 8 weeks following enrollment
|
|
|
Distribution of patient reported health-related quality of life (HRQoL) measures through European Organisation for Research and Treatment of Cancer Quality of Life- Core Questionnaire in participants treated with nivolumab for R/M SCCHN
Periodo de tiempo: At enrollment, Up to 8 weeks
|
At enrollment, Up to 8 weeks
|
|
|
Distribution of patient reported HRQoL measures through EQ-5D-5L in participants treated with nivolumab for R/M SCCHN
Periodo de tiempo: At enrollment, Up to 8 weeks
|
At enrollment, Up to 8 weeks
|
|
|
Distribution of patient reported HRQoL measures through European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module in participants treated with nivolumab for R/M SCCHN
Periodo de tiempo: At enrollment, Up to 8 weeks
|
At enrollment, Up to 8 weeks
|
|
|
Distribution of patient reported HRQoL measures through CTSQ in participants treated with nivolumab for R/M SCCHN
Periodo de tiempo: At enrollment, Up to 8 weeks
|
Cancer Therapy Satisfaction Questionnaire (CTSQ)
|
At enrollment, Up to 8 weeks
|
|
Distribution of patient reported HRQoL measures through WPAI:GH in participants treated with nivolumab for R/M SCCHN
Periodo de tiempo: At enrollment, Up to 8 weeks
|
Work Productivity and Activity Impairment Questionnaire: General Health (WPAI:GH)
|
At enrollment, Up to 8 weeks
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
13 de agosto de 2020
Finalización primaria (Actual)
18 de octubre de 2021
Finalización del estudio (Actual)
18 de octubre de 2021
Fechas de registro del estudio
Enviado por primera vez
8 de septiembre de 2021
Primero enviado que cumplió con los criterios de control de calidad
24 de septiembre de 2021
Publicado por primera vez (Actual)
6 de octubre de 2021
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
5 de mayo de 2022
Última actualización enviada que cumplió con los criterios de control de calidad
2 de mayo de 2022
Última verificación
1 de mayo de 2022
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias por tipo histológico
- Neoplasias
- Neoplasias por sitio
- Neoplasias Glandulares y Epiteliales
- Neoplasias de Cabeza y Cuello
- Neoplasias De Células Escamosas
- Carcinoma
- Carcinoma De Células Escamosas
- Carcinoma de células escamosas de cabeza y cuello
- Mecanismos moleculares de acción farmacológica
- Agentes antineoplásicos
- Agentes antineoplásicos inmunológicos
- Inhibidores de puntos de control inmunitarios
- Nivolumab
Otros números de identificación del estudio
- CA209-7F9
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .